Enveric Biosciences Unveils Positive Safety and Pharmacology Data for EB-003 [Microdose]
Tuesday, October 15, 2024 1 min read
Key Takeaway: Enveric Biosciences has released new preclinical data for EB-003, highlighting its ability to effectively target serotonergic receptors while significantly reducing the risks of cardiovascular and CNS side effects. This positions EB-003 as a promising candidate for non-hallucinogenic treatment options for mental health disorders.
Price reaction · baseline $74.16 (2024-10-14 close) · hit pre-market · clean, no other ENVB news in the window
day 0 close
+2.7%
Market Sentiment Analysis
POSITIVE FACTORS
EB-003 shows promising safety profile in preclinical results.
Targets serotonergic receptors effectively.
Minimizes cardiovascular and CNS side effects.
Potential as a non-hallucinogenic treatment for mental health.
Full Press Release Details
New preclinical results showcase EB-003’s ability to target serotonergic receptors while minimizing risks of cardiovascular and CNS side effects, advancing its potential as a non-hallucinogenic treatment for mental health disorders.
Full Article >>
Frequently Asked Questions
What is EB-003?
EB-003 is a treatment candidate developed by Enveric Biosciences aimed at mental health disorders.
What are the benefits of EB-003?
EB-003 targets serotonergic receptors while minimizing cardiovascular and CNS side effects.
What type of data was released for EB-003?
Enveric Biosciences unveiled positive preclinical safety and pharmacology data for EB-003.
Is EB-003 a hallucinogenic treatment?
No, EB-003 is designed as a non-hallucinogenic treatment option.